By admin 
In a significant move to address the stagnant survival rates of pediatric bone cancer, CureSearch for Children’s Cancer has announced the recipient of its prestigious Acceleration Initiative Award, granting more than $900,000 to a pioneering research project at the David Geffen School of Medicine at UCLA. Led by Dr. John Lee, an associate professor in residence in the Division of Hematology/Oncology, the research aims to revolutionize the treatment landscape for metastatic Ewing sarcoma (ES), a disease that has seen little therapeutic progress over the last four decades. This funding marks a critical juncture in pediatric oncology, focusing on the development of a novel immunotherapy that enhances the body’s natural defenses to target and eliminate aggressive cancer cells that have spread beyond the primary tumor site.
The project, which centers on the strategic enhancement of Chimeric Antigen Receptor (CAR) T-cell therapy, arrives at a time when the medical community is calling for more precise and less toxic alternatives to conventional treatments. By integrating Interleukin-18 (IL-18) into CAR T-cell frameworks, Dr. Lee’s team seeks to overcome the biological barriers that have historically rendered immunotherapy less effective against solid tumors like Ewing sarcoma. The initiative is designed with a rigorous three-year timeline, aiming to move from preclinical validation to human clinical trials with unprecedented speed, offering a glimmer of hope to families facing the most dire diagnoses.
The Critical Challenge of Metastatic Ewing Sarcoma
Ewing sarcoma is the second most common type of primary bone cancer in children and young adults, characterized by the presence of small round blue cells and usually driven by a specific genetic translocation known as EWS-FLI1. While localized Ewing sarcoma has a five-year survival rate of approximately 70% to 75% due to aggressive combinations of surgery, radiation, and intensive chemotherapy, the prognosis for patients with metastatic disease remains catastrophic. For children whose cancer has spread to the lungs, other bones, or bone marrow at the time of diagnosis, the survival rate plummets to as low as 15% to 30%.
The current standard of care for Ewing sarcoma relies heavily on cytotoxic chemotherapy regimens that were largely established in the 1970s and 1980s. While these treatments can be effective at shrinking tumors initially, they often come with severe, long-term side effects, including secondary cancers, heart damage, and infertility. Furthermore, once the disease becomes metastatic or relapses, it frequently develops resistance to conventional drugs, leaving oncologists with few viable options. This "therapeutic plateau" has necessitated a shift toward precision medicine and immunotherapy, which aims to target cancer cells specifically while sparing healthy tissue.
The Innovation: Enhancing CAR T-Cell Potency with IL-18
Dr. Lee’s research focuses on CAR T-cell therapy, a form of treatment where a patient’s own T-cells—the "soldiers" of the immune system—are extracted, genetically engineered to recognize a specific protein on cancer cells, and then infused back into the patient. While CAR T-cell therapy has achieved remarkable success in treating blood cancers like leukemia and lymphoma, its efficacy in solid tumors has been limited. Solid tumors create a "suppressive microenvironment" that effectively shuts down immune cells or prevents them from penetrating the tumor mass.
To address this, Dr. Lee’s team is incorporating Interleukin-18 (IL-18) into the CAR T-cell design. IL-18 is a potent pro-inflammatory cytokine that plays a crucial role in activating both the innate and adaptive immune systems. In the context of Ewing sarcoma, the inclusion of IL-18 acts as a "booster," not only making the CAR T-cells more resilient against the tumor’s defenses but also signaling other immune cells to join the attack. This dual-action approach is intended to turn a "cold" tumor—one that the immune system ignores—into a "hot" tumor that is actively targeted by the body’s natural defenses.
Preclinical data suggests that this reinforced immune response can more effectively seek out and destroy metastatic lesions, which are often microscopic and difficult to target with traditional radiation or surgery. By arming the immune system with these high-tech tools, the research team hopes to create a durable response that prevents the recurrence of the disease.
The Acceleration Initiative: A Fast-Track to Clinical Application
The funding for this project comes through CureSearch’s Acceleration Initiative, a program specifically designed to bridge the "Valley of Death" in drug development—the gap between laboratory discovery and clinical implementation. Many promising pediatric cancer treatments fail to reach patients because of a lack of funding for the expensive transition into human trials. The Acceleration Initiative selects projects based on their high potential for clinical impact and their ability to reach the clinic within a three-year window.
The $900,000 investment in Dr. Lee’s project is part of a broader strategy to ensure that innovative science does not sit idle on a lab bench. The award requires rigorous milestone reporting and a clear pathway to FDA approval. By focusing on projects that are "clinic-ready," CureSearch aims to reduce the time it takes for new therapies to reach the bedside, a factor that is particularly vital for children with metastatic Ewing sarcoma who do not have the luxury of time.
A Collaborative Funding Model Rooted in Legacy
The funding of Dr. Lee’s research is a testament to a growing collaborative model in the non-profit sector. The grant is supported in part by the Rally Foundation for Childhood Cancer Research and three CureSearch Legacy Funds: The Garret Collins Legacy Fund, The Nick Currey Fund, and The Sam Schneider Legacy. These funds were established by families who have lost children to Ewing sarcoma, turning their personal tragedies into a driving force for scientific advancement.
The involvement of these legacy funds highlights the human cost of the disease. Sam Schneider’s family has emphasized the need for early detection and better treatments, noting that Sam’s cancer was only detected after it had become metastatic—a common and tragic occurrence in Ewing sarcoma cases. Similarly, the family of Nick Currey has advocated for less toxic therapies, noting that the harshness of current treatments is often as devastating as the disease itself. By pooling resources from multiple organizations and private donors, the Acceleration Initiative Award creates a robust financial foundation for high-stakes research that might otherwise be considered too risky for traditional government grants.
Chronology of Progress in Pediatric Immunotherapy
The path to Dr. Lee’s current research has been built on decades of incremental progress in the field of immunology and oncology:
- 1990s-2000s: The identification of the EWS-FLI1 fusion protein as the primary driver of Ewing sarcoma provided a theoretical target for precision therapy, though the protein itself proved difficult to "drug" directly.
- 2010s: The emergence of CAR T-cell therapy for B-cell malignancies revolutionized the field, prompting researchers to explore how these "living drugs" could be adapted for solid bone and soft tissue tumors.
- 2017-2021: Early-phase clinical trials for various immunotherapies in pediatric sarcomas showed limited success, identifying the "immunosuppressive microenvironment" as the primary obstacle to overcome.
- 2023: Dr. John Lee’s team at UCLA develops a preclinical model using IL-18 to enhance CAR T-cell function, showing promising results in laboratory settings.
- 2024: CureSearch awards the Acceleration Initiative grant to Dr. Lee, officially launching the three-year countdown to clinical application.
Broader Implications for Pediatric Oncology
The implications of Dr. Lee’s research extend beyond Ewing sarcoma. If the IL-18-enhanced CAR T-cell therapy proves successful in clinical trials, it could serve as a blueprint for treating other recalcitrant solid tumors in children, such as osteosarcoma and neuroblastoma. These cancers share similar challenges regarding the tumor microenvironment and the need for targeted, less toxic interventions.
Furthermore, this project represents a shift in how pediatric cancer research is prioritized. Because pediatric cancers are considered "rare" compared to adult cancers, they often receive significantly less funding from pharmaceutical companies. The role of organizations like CureSearch and the Rally Foundation is essential in de-risking early-stage research, making it more attractive for future large-scale investment and commercial development.
The focus on "targeted, less toxic" therapies is also a response to the growing awareness of "survivorship" issues. As more children survive their initial cancer diagnosis, the medical community is increasingly concerned with the quality of life after treatment. Immunotherapies like the one proposed by Dr. Lee offer the potential for a "cleaner" kill of cancer cells, reducing the collateral damage to developing organs and systems in growing children.
Conclusion and Future Outlook
As Dr. John Lee and his team at UCLA begin the next phase of their research, the pediatric oncology community remains cautiously optimistic. The combination of cutting-edge genetic engineering and the potent biological signaling of IL-18 represents one of the most sophisticated approaches to Ewing sarcoma to date. With the backing of CureSearch and the dedicated support of families through legacy funds, the project is well-positioned to meet its ambitious goal of reaching the clinic within three years.
For the children currently battling metastatic Ewing sarcoma, and for those who will be diagnosed in the future, this research is more than just a scientific endeavor; it is a vital lifeline. The transition from the "devastating" prognosis mentioned in current medical literature to a future of manageable, curable disease depends on the success of these innovative, accelerated research initiatives. As the project moves forward, it serves as a reminder that while the challenges of pediatric cancer are immense, the collective effort of scientists, donors, and families continues to push the boundaries of what is possible in the fight for a cure.